General Information of Drug (ID: DMO21H5)

Drug Name
PMID18078750C1b Drug Info
Synonyms GTPL8627; BDBM50286724
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44377139
TTD Drug ID
DMO21H5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Neutral endopeptidase (MME)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LCZ696 DMLFX7K Heart failure BD10-BD13 Approved [2]
Candoxatril DMHJCGV Hypertension BA00-BA04 Phase 3 [3]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [4]
SLV 306 DMCDON3 Acute decompensated heart failure BD1Z Phase 2 [5]
SLV-334 DMXCJKY Brain injury NA07.Z Phase 2 [6]
VX-15 DMLWM4G Huntington disease 8A01.10 Phase 2 [7]
Sampatrilat DMXTOVE Hypotension BA20-BA21 Phase 2 [8]
SLV-338 DM7WKTM Cardiovascular disease BA00-BE2Z Phase 1 [9]
GW-796406 DMQ46DN Hypotension BA20-BA21 Phase 1 [4]
Debio 0827 DMQIEFB Chronic pain MG30 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Carboxypeptidase A1 (CPA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DL-benzylsuccinic acid DMHI9ZJ Discovery agent N.A. Investigative [11]
2-Thiomethyl-3-Phenylpropanoic Acid DMCEK6N Discovery agent N.A. Investigative [12]
SQ-14603 DMJW8NV Discovery agent N.A. Investigative [13]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carboxypeptidase A1 (CPA1) TT3LJ6G CBPA1_HUMAN Inhibitor [1]
Neutral endopeptidase (MME) TT5TKPM NEP_HUMAN Inhibitor [1]

References

1 Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
4 Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
5 The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
6 Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
9 Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
10 Clinical pipeline report, company report or official report of Debiopharm (2011).
11 A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1587).
13 Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103.